<DOC>
	<DOC>NCT01461018</DOC>
	<brief_summary>The purpose of this study is to assess the long-term efficacy, tolerability, and safety of IgPro20 in subjects with primary immunodeficiency (PID) as an extension to the preceding follow-up study ZLB07_001CR (NCT01458171).</brief_summary>
	<brief_title>Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>Subjects who have completed the preceding followup study ZLB07_001CR. Written informed consent by the subject/parent/legally acceptable representative. Written assent for an underage subject (â‰¥7 years and &lt;20 years of age at the time of obtaining informed consent), according to the competencies of the subject. Pregnancy or nursing mother. Participation in a study with an investigational medicinal product (IMP) within 3 months prior to enrollment except for study ZLB07_001CR. Subjects who are planning to donate blood during the study. Known or suspected antibodies to the IMP, or to excipients of the IMP. Treatment with another immunoglobulin G (IgG) within 3 months prior to the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>Primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>